Alprazolam
- Generic Name
- Alprazolam
- Brand Names
- Niravam, Xanax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H13ClN4
- CAS Number
- 28981-97-7
- Unique Ingredient Identifier
- YU55MQ3IZY
- Background
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.
- Indication
Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.
Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.
- Associated Conditions
- Generalized Anxiety Disorder, Panic Disorder
Premedication With Alprazolam and Midazolam for Upper Gastrointestinal Endoscopy
- Conditions
- Diagnostic Esophagogastroduodenoscopy
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 136
- Registration Number
- NCT03130842
- Locations
- 🇮🇷
Department of Gastroenterology, Alzahra Hospital, Isfahan, Iran, Islamic Republic of
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT03012334
- Locations
- 🇨🇦
Algorithme Pharma, Mount Royal, Quebec, Canada
Pharmacovigilance in Gerontopsychiatric Patients
- Conditions
- DementiaDepressionSchizophreniaPsychosomatic DisordersAnxiety Disorders
- Interventions
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 407
- Registration Number
- NCT02374567
- Locations
- 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪Hannover Medical School, Hannover, Germany
Staccato Alprazolam and Photoparoxysmal Response
- Conditions
- Epilepsy
- Interventions
- Drug: A=PlaceboDrug: E=Placebo
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02351115
- Locations
- 🇺🇸
New York University Epilepsy Center, New York, New York, United States
🇺🇸Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States
🇺🇸University of Pennsylvania - Penn Epilepsy Center, Philadelphia, Pennsylvania, United States
Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy
- Conditions
- Diagnostic Esophagogastroduodenoscopy
- Interventions
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2013-10-18
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 220
- Registration Number
- NCT01949038
- Locations
- 🇮🇷
Private Outpatient Clinic of Gastroenterology, Isfahan, Iran, Islamic Republic of
Bioequivalence Trial of Alprazolam 0.25 mg Tablets
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01853956
Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T
- Conditions
- Psychotropic Drugs Effects
- Interventions
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01747590
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Bioequivalence Trial of Alprazolam 2 mg Tablets
- Conditions
- Anxiety Disorders
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT01745575
Bioequivalence Trial of Alprazolam 0.5 mg Tablets
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01745562
Spectroscopic Imaging at 4T: A Drug Challenge Study
- Conditions
- AOD Effects and Consequences
- Interventions
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 7
- Registration Number
- NCT01577706
- Locations
- 🇺🇸
McLean Imaging Center, McLean Hospital, Belmont, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.